Peer-Reviewed Publication
Arthritis Res Ther2026;28(1)March 25, 2026Journal Article
Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States.
Marina Magrey1, Milena A Gianfrancesco2, Lara Fallon3, Arne Yndestad4, Ivana Vranic5, Yuqin Wei6, You-Li Ling7, David Gruben8, Jeffrey R Curtis9
1Department of Rheumatology, Case Western Reserve University, University Hospitals, Cleveland, OH, USA.
2Pfizer Inc, 66 Hudson Boulevard E, New York, NY, 10001, USA. Milena.Gianfrancesco@pfizer.com.
3Pfizer Inc, Montreal, QC, Canada.
4Pfizer Inc, Oslo, Norway.
5Pfizer Ltd, Tadworth, UK.
6Komodo Health, San Francisco, CA, USA.
7Pfizer Inc, 66 Hudson Boulevard E, New York, NY, 10001, USA.
8Pfizer Inc, Groton, CT, USA.
9Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Abstract
BACKGROUND: This United States (US)-based claims analysis evaluated the real-world safety of tofacitinib versus biologic treatments in patients with psoriatic arthritis (PsA). Risk of serious infections, myocardial infarction (MI) or stroke, venous thromboembolism (VTE), and malignancy (excluding non-melanoma skin cancer) were assessed using data from a US real-world database of administrative dat…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans